Group 1 - The company Shuanglu Pharmaceutical announced on November 3 that its adenosylmethionine has been successfully awarded a bid [2] - The planned bidding regions include Shandong, Hubei, Tianjin, Shanxi, and Ningxia [2]

Core Viewpoint - Shuanglu Pharmaceutical has successfully launched its nitroglycerin spray, and the market promotion is progressing in an orderly manner [2] Company Summary - Shuanglu Pharmaceutical's nitroglycerin spray has been officially launched [2] - The company is actively promoting the product in the market [2]

Core Viewpoint - The company is preparing to submit the NDA for its GLP-1 long-acting product after addressing feedback and completing necessary documentation [2] Group 1 - Investors inquired about the delay in the NDA submission for the GLP-1 long-acting product, which has been pending for nearly a year [2] - The company confirmed that it is currently organizing and refining the required materials for the NDA submission and is conducting drug inspections [2] - The company will provide updates on the progress of the NDA submission as new developments arise [2]

Group 1 - The company Shuanglu Pharmaceutical has won the bid for adenosylmethionine in the 11th batch of centralized procurement [2] - The winning price for the product is set at 9.26 per unit [2] - The regions where the product has been awarded include Shandong, Hubei, Tianjin, Shanxi, and Ningxia [2]

Group 1 - The company holds a 0.34% stake in XuanZhu Biotechnology Co., Ltd., amounting to 1.7808 million shares [2] - The investment in XuanZhu Biotechnology was made through a capital increase, with a total investment of 20.6346 million [2] - The average cost per share for the company is 11.59 yuan [2]

Group 1 - The core issue is the suspension of the review for the long-acting follicle-stimulating hormone by the company due to reaching the review deadline and currently awaiting supplementary comments [2]

Core Viewpoint - The company is preparing to submit documentation for its long-acting GLP-1 product, indicating progress in its development pipeline [1] Group 1 - The company announced on November 3 that it is organizing materials for submission regarding its GLP-1 long-acting product [1]

Core Viewpoint - The company has successfully launched its nitroglycerin spray and is currently advancing its market promotion efforts [1] Company Summary - The nitroglycerin spray has officially been released to the market [1] - Market promotion for the product is progressing in an orderly manner [1]

Core Viewpoint - The company has successfully won a bid for adenosylmethionine in the 11th batch of centralized procurement, indicating a positive development in its product offerings and market presence [1] Group 1: Company Information - The company, 双鹭药业 (Shuanglu Pharmaceutical), announced on November 3 that its product adenosylmethionine has been awarded a bid [1] - The proposed bidding regions for the product include Shandong, Hubei, Tianjin, Shanxi, and Ningxia [1]

Core Viewpoint - 双鹭药业 is a leading enterprise in the research and production of genetic engineering drugs in China, focusing on the development of related pharmaceuticals and demonstrating strong technical research advantages [1] Group 1: Business Performance - In Q3 2025, 双鹭药业 reported revenue of 459 million yuan, ranking 84th out of 110 in the industry, with the industry leader, 华东医药, generating 32.664 billion yuan [2] - The net profit for the same period was 141 million yuan, placing the company 44th in the industry, while the top performer, 恒瑞医药, achieved a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 双鹭药业's debt-to-asset ratio was 5.44%, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for the same period was 61.60%, higher than the industry average of 57.17%, reflecting good profitability [3] Group 3: Executive Compensation - The chairman, 徐明波, received a salary of 429,400 yuan in 2024, an increase of 44,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.35% to 54,800, while the average number of circulating A-shares held per shareholder increased by 6.78% to 15,600 [5] - Among the top ten circulating shareholders, 香港中央结算有限公司 held 12.1213 million shares, an increase of 3.4299 million shares from the previous period [5]